11，Gavg R,Yusuf S.Overview of randomized trial of angiotensin -converting enzyme inhibitors on mortality and morbidity in patients with heart failure.Collaborative Group on ACE inhibitors.JAMA,1995;273(18):1450
22，CIBIS-Ⅱ Investigators and Committees.The cardiac insufficiency bisoprolol study Ⅱ(CIBIS-Ⅱ)a randomised trial.Lancet,1999;353(9146):9
33，MERIT-HF Study Group.Effect of metoprolol CR/XL in chronic heart failure:Metoprolol CR/XL Randomised Intervention Trial in congestive Heart Failure(MERIT-HF).Lancet,1999;353(9169):2001
4[1]Barghi C,Boschi S,Ambrosioni E,et al.Evidence of partial escape of RAA blockade in patients with acute MI treated with ACE inhibitors.J Clin Pharmacol,1993,33∶40-45.
5[2]Pitt B."Escape"of aldosterone sterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor:implications for therapy.Cardiovasc Drugs Ther,1995,9∶145-149.
6[3]Struthers AD.Aldosterone sterone escape during angiotension-converting enzyme inhibitor therapy in chronic heart failure.J Card Fail,1996,2∶47-54.
7[4]The RALES Inestigators.Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure.Am J Cardiol,1996,78∶902-907.
8[5]Faiez Z,Brigitte D,Francois A.Treatment of congeative heart failure interfering the aldosterone-cardiac extracellular matrix relationship.Hypertension,2001,38∶1227-1232.
9[6]Schon DC,Jahn HA,Pelletier BC.Dose-related cardiovascular effect of spironolactone.Am J Cardiol,1993,71∶40A-45A.
10[7]Zannad F.Aldosterone and heart failure.Eur heart J,1995,16(Suppl N)∶98-102.
2Davila DF,Donis JH, Bellabarba G, et al. Cardiac afferents and neurohormonal activation in congestive heart failure. Med Hypotheses, 2000,54(2) :242.
3Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators, N Engl J Med, 1999,341(10) :709.
